How often are you recommending adjuvant pembrolizumab for resected stage IIB/C melanoma patients?

Based on the KEYNOTE-716 study and Dec 2021 FDA approval

Answer from: Medical Oncologist at Academic Institution

Will refer to the results from the KEYNOTE-716 trial:The data cutoff for the analysis (in January 2022), median follow-up was 27.4 months (interquartile range = 23.1–31.7 months). Pembrolizumab significantly improved distant metastasis–free survival vs placebo (hazard ratio [HR] = 0.64, ...

Comments

Medical Oncologist at University of Utah
Update - Luke et al., Journal of Clinical Oncology...

Answer from: Medical Oncologist at Academic Institution

The patient should be enrolled on KEYNOTE-716 (Phase 3 study of pembro vs placebo for high risk stage II melanoma including T3b, T4a, T4b) - https://clinicaltrials.gov/ct2/show/NCT03553836?term=KEYNOTE+716&rank=1.

Comments

Medical Oncologist at St Jude Heritage Medical Group
So, we can surmise from your answer that since KEY...

Please select the option that best describes you:

How often are you recommending adjuvant pembrolizumab for resected stage IIB/C melanoma patients?

Related Questions